Glaxo places PR business for HIV drugs under review

Share this article:

GlaxoSmithKline has placed the PR business for its HIV medications franchise in review.
The incumbent agency, Chicagobased PCI Public Communications, is not participating in the review.
A GSK spokeswoman declined to comment on the review, citing corporate policy that "any of our agency dealings is confidential."

 

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions